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Abstract
Mutations in the dystrophin and sarcoglycans genes result in muscular dystrophies 
causing severe disability and premature death and where no effective treatment is 
available. New therapeutic approaches targeting secondary disease mechanisms have a 
strong translational potential. Dystrophic muscle damage triggers release of ATP whilst 
loss of ecto-ATPase activity of sarcoglycan further elevates extracellular ATP (eATP) 
levels. Such high eATP activates P2X7 purinoceptors on immune cells; these contribute 
to chronic inflammatory and immune responses that exacerbate the dystrophic 
pathology. Dystrophin mutations coincide with a significant P2X7 upregulation in 
Duchenne muscular dystrophy (DMD) muscle and alter receptor signalling in mouse 
dystrophic myoblasts and myofibres. P2X7 overexpression combined with the eATP-
rich environment lead to cell dysfunction and death and ultimately to ineffective 
regeneration. P2X7 is therefore a therapeutic target for reducing damaging 
inflammation and supporting the repair of dystrophic muscles. Accordingly, genetic 
ablation and pharmacological inhibition of the eATP-P2X7 axis alleviated dystrophic 
phenotypes in mouse models of dystrophinopathy and sarcoglycanopathy. Thus, P2X7 
inhibitors are good candidates for rapid re-purposing for the treatment of these highly 
debilitating diseases. Such therapy is not constrained by causative mutations, so it 
would be suitable for all patients. Moreover, it appears effective in alleviating both 
muscle and non-muscle symptoms.
Highlights
Inflammation is a pathological hallmark of muscular dystrophies 
Dystrophin and/or sarcoglycans loss alter eATP degradation and P2X7 signalling in muscles
Treatment of this purinergic abnormality reduces damaging inflammation and supports 
dystrophic muscle repair
P2X7 inhibitors are good candidates for rapid re-purposing as therapeutics in several 
muscular dystrophies 
Muscular dystrophies (MD) are a group of inherited diseases of a varying severity. The most 
common, Duchenne muscular dystrophy (DMD), causes disability and death of young men 
due to progressive muscle degeneration aggravated by sterile inflammation. DMD is also 
associated with a loss of bone mineral density, an independent disease manifestation 
contributing to impaired ambulation, and with a cognitive impairment [1●●]. 
Sarcoglycanopathies (LGMD2C-F) caused by mutations in the γ,α, β and δ sarcoglycan genes 
are heterogeneous for onset and severity [2●●]. No treatment offers any long-term 
improvement for any of these diseases. 
Purinergic signalling in healthy and diseased muscle
Skeletal muscle (SM) is responsible for movement and posture maintenance but also 
thermogenesis and metabolic homeostasis. All these functions require ATP and, at 5–10 mM 
range, its cytosolic concentration within the SM cell [3] is particularly high.
In response to stimuli or muscle activity, muscle cells release small amounts of ATP [4]. This 
extracellular ATP (eATP) becomes a signal acting via specific ionotropic (P2X) or 
metabotropic (P2Y) purinergic receptors, evoking increased intracellular Ca2+ levels and a 
range of downstream effects (reviewed in [5,6]).
Damage or death of muscle cells result in large amounts of eATP being released, reaching 
millimolar concentrations in the injury area. This eATP becomes an important 
danger/damage associated molecular patter (DAMP) signal, triggering inflammatory 
responses. The critical role in this process is played by the P2X7, responding to much higher 
(> 1mM) eATP concentrations than other purinoceptors and being expressed by virtually all 
the immune cell types [7●]. Importantly, acute muscle inflammation is essential for the 
removal of dead and dying cells and ultimately regeneration [8]. However, the continuous, 
high level eATP-mediated stimulation accompanying a chronic muscle damage and one that 
is typical for MD, can exacerbate disease symptoms.
The mechanism of this purinergic phenotype in MD is complex: eATP concentrations are 
regulated by extracellular hydrolysing enzymes (nucleotidases) [9]. Importantly, 25% of 
eATP degradation in muscles has been attributed to α-sarcoglycan, the muscle-specific ATP 
hydrolase [10●●,11] that also is a member of the dystrophin-associated protein (DAP) 
complex. Thus, α-sarcoglycan is lost from the sarcolemma in DMD and also in limb-girdle 
muscular dystrophies (LGMD2C-F). Given that ectoATPases cannot cope with eATP in 
excess of 100 M [12], the balance between ATP release and its degradation in DMD and 
sarcoglycanopathies is altered even further, with eATP levels being increased dramatically. 
By over-activating purinoceptors on both muscle and immune cell, high eATP contributes to 
abnormal intracellular Ca2+ homeostasis in the former (see below). It also triggers the 
damaging chronic inflammatory and immune responses, which are found in dystrophic 
muscles [13].
Inflammation and immune responses in muscular dystrophy
Several studies demonstrated that chronic muscle inflammation plays a crucial role in the 
pathogenesis of DMD. Specifically, anti-cytokine therapies or treatments inducing depletion 
of CD4, CD8 lymphocytes, neutrophils, dendritic cells or macrophages (that are all found to 
infiltrate necrotic muscle) significantly improved the dystrophic phenotype in vivo [13, 19-
27]. Muscles of the mdx mouse, the most commonly used model of DMD, contain 20 times 
more macrophages and 7 times more dendritic cells than is found in healthy individuals [28]. 
Interestingly, transmission of pathology from mdx to healthy mice by adoptive transfer of 
primed immune cells [23] and the presence of specific cytotoxic T-cell receptor gene 
rearrangements in DMD [19] also suggest breakdown in the peripheral tolerance to self-
molecules. Moreover, dystrophin is immunogenic: The presence of alloreactive T-cells 
against dystrophin epitopes has been found in DMD patients [29●●] and exon skipping and 
suppression of stop codons used to re-express dystrophin in DMD patients [30] can prime or 
recall dystrophin-specific T-cell responses. Such problems have been documented in both 
experimental and clinical trials [31]. 
Therefore, suppression of inflammatory/immune responses can not only reduce the direct 
dystrophic muscle damage evoked by infiltrating cells but is also pre-requisite for successful 
molecular therapies. Given that the mechanism underlying the dystrophic inflammation 
involves “danger signals” activating P2X7 expressed by all the muscle-infiltrating immune 
cells, this purinoceptor emerges as the key player. 
P2X7 expression in dystrophic muscle cells
Furthermore, alongside P2X7 expression and activation in inflammatory cells, studies 
showed a dramatic up-regulation of this purinoceptor in DMD patients’ muscle biopsy 
samples [32] and also in muscle and isolated muscle cells from the mouse model of DMD 
[33-35]. P2X7 overexpression was particularly evident on mdx fast skeletal myofibres, where 
it was linked to enhanced sarcolemma permeability [35●]. Crucially, fast muscle fibres are 
preferentially affected in DMD [1]. 
Whilst P2X7 overexpression has not been documented for muscle cells from DMD patients, 
significant functional abnormalities of this receptor in DMD lymphoblasts have been 
described [36●]. This might indicate a DMD-evoked purinergic abnormality being common 
across species and also cell types. 
When exposed to eATP, dystrophic mdx myoblasts respond with increased cytosolic Ca2+ 
influx and IL-1 release [34,37]. Interestingly, P2X7 purinoceptor upregulation and NLRP3 
inflammasome activation were also detected in the dysferlin knockout, a mouse model of yet 
another muscular dystrophy (LGMD2B). These findings suggest that dystrophic muscle cells 
are not just targets for but can also actively contribute to the aforementioned inflammatory 
process through purinergic signaling [37]. 
Moreover, high concentrations of eATP have been shown to activate abnormal Ca2+ influx 
into dystrophic muscle cells and alter their migration [38]. Treatment with apyrase, an eATP 
degrading enzyme, have reduced intracellular Ca2+ levels in mdx fibers [39]. While both P2Y 
and P2X components were noticeable [33], the ERK phosphorylation and the large pore 
opening indicated involvement of P2X7 purinoceptors [34]. This large pore opening, dye 
permeability and, in some circumstances, cell death via cell-specific and even unique 
mechanisms, e.g. pyroptosis and autosis are consequences of P2X7 activation under 
appropriate conditions [40]. Indeed, activation of the large pore was found triggering 
autophagic death [41] and increased release of active MMP-2 matrix metalloprotease from 
dystrophic muscle cells [38]. Specific P2X7 antagonists reduced these effects, confirming 
that this receptor contributes significantly to the deregulated homeostasis in dystrophic 
muscles. 
In conclusion, large amounts of eATP released from dead and damaged dystrophic muscle 
cells, combined with reduced degradation of eATP due to loss of ecto-ATPase activity of α-
sarcoglycan result in an environment consistent with over-activation of ATP receptors. The 
property of P2X7 making it activated by higher eATP, and the increased expression of P2X7 
in dystrophic cells result in a strong and prolonged activation of this receptor in dystrophic 
fast myofibres and myoblasts. The consequences include increased sarcolemma permeability 
[35●] contributing to the death of dystrophic myofibres [1] and the reduced myogenic 
potential of dystrophic muscles and therefore inefficient regeneration.
Finally, P2X7 activation contributes to severe and damaging sterile inflammation in a 
mechanism akin to that in other inflammatory diseases [40, 42] but also by inducing NLRP3 
inflammasome activation and IL-1  release from dystrophic muscle cells themselves [37]. 
In view of the multiple mechanisms by which P2X7 contribute to the pathology (Figure 1), 
this purinoceptor emerges as an attractive therapeutic target, where its inhibition could reduce 
unwanted inflammatory responses but also reduce damage to myofibres and support the 
regenerative potential of dystrophic myoblasts.
P2X7 blockade as an approach to treat muscular dystrophies
Indeed, we and others have shown the therapeutic impact of both genetic ablation and 
pharmacological blockade of P2X7 in mdx mice in vivo. The mdx mouse is the animal model 
most widely used in pre-clinical studies of novel therapeutic approaches. 
Using molecular and histological methods we demonstrated that ablation of P2X7 in mdx 
(mdx/P2X7-/-) mice resulted in a profound attenuation of dystrophic symptoms [43●●]. There 
were improvements in muscle structure, decreased inflammatory and pro-fibrotic molecular 
signatures. Comparisons of immune cell populations showed that pan-macrophage marker 
levels were lower and the F4/80 to CD163 (pro-inflammatory to pro-regenerative) ratio was 
significantly reduced in mdx/P2X7-/- compared to mdx muscle. While the CD4 and CD8 
lymphocyte numbers were not affected, a significant increase in Foxp3 and IL-12α 
expression in mdx/P2X7-/- muscles indicated a shift towards Treg cells [43●●]. Thus, P2X7 
ablation ameliorated tissue inflammation and promoted Treg cell functions, known to suppress 
dystrophic muscle damage [44●].  These improvements were evident both at the peak of 
disease severity but also at 20 months in leg, diaphragm and cardiac muscles (the heart 
outcome being important because long-surviving patients die of cardiac failure). Notably, 
functional analyses showed increased muscle strength ex vivo and also in vivo. Furthermore, 
in addition to the alleviation of muscle disease and decreased inflammation, reduced non-
muscle symptoms including cognitive and bone improvements, were evident in mdx/P2X7-/- 
mice [43●●,45]. The cognitive recovery is important given that severe impairment affects one-
third of patients, further reducing the quality of life of sufferers and their families. It is 
currently not known whether this effect was due to P2X7 ablation in specific brain cells or 
because of reduced levels of inflammatory mediators reaching the dystrophic brain through 
its leaky blood-brain barrier [46].
Bone deformities contribute significantly to the loss of ambulation in DMD patients. P2X7 
plays significant roles in bone cells. Its ablation did not exacerbate but corrected the bone 
phenotype and the reduced inflammatory signature in mdx/P2X7-/- muscles may again 
translate into the reduced bone loss [43●●,47]. 
These wide-ranging improvements reflected the impact of P2X7 activation on multiple 
disease processes (Figure 1). While the mechanism(s) require further studies, such a 
clinically-relevant therapeutic strategy that modifies both muscle and non-muscle symptoms 
represents a significant progress. 
Therapeutic potential of the pharmacological inhibition of P2X7 in dystrophies
Pharmacological P2X7 inhibitors are available and improvements were observed even 
following short-term treatment of mdx mice with broad-spectrum compounds such as CBB 
and ox-ATP [32,43]. The therapeutic effect of ox-ATP also included reduced tissue 
inflammation and increased Treg cells [32]. Other studies reported suramin treatment reducing 
mdx muscle damage [48,49]. Furthermore, in α-sarcoglycan null mice, blockade of the 
eATP/P2X purinergic pathway also delayed the progression of muscle disease and reduced 
inflammation [50●]. These data suggest that pharmacological purinergic antagonism might be 
therapeutic in DMD and also LGMD2C-F. However, ox-ATP and suramin used in those 
studies are non-specific. These drugs have not been optimized for potency and selectivity at 
the P2X7 receptor or cleared for use in humans. Yet, all the current data identify this receptor 
as the main player in the dystrophic pathology and so the specific P2X7 blockade emerges as 
an attractive target for translational approaches in muscular dystrophy. 
More selective P2X7 inhibitors have been developed and some of these (e.g. AZD9056 and 
CE-224,535) used in phase 2 clinical trials in inflammatory diseases [51-53]. Such drugs, if 
re-purposed for DMD, would offer the most specific treatment effect. However, none of these 
compounds have been approved as medicines and none tested in children. On the other hand, 
Zidovudnine (azidothymidine, AZT), one of the mainstay nucleoside reverse transcriptase 
inhibitors, is a potent P2X7 blocker [54] binding the same allosteric site as other P2X7 drugs 
[55,56●●]. A short-term AZT treatment in mdx mice attenuated the key disease parameters 
causing reduced sarcolemma permeability, decreased inflammation in leg and heart muscles 
and producing increased muscle strength. Recovery was evident without any detectable side 
effects [56]. Given these results, AZT with its established pharmacological profile also in the 
pediatric population, is a candidate for rapid re-purposing for the treatment of this highly 
debilitating and invariably lethal disease. 
Conclusions
Dystrophic muscle environment is consistent with elevates levels of eATP leading to 
damaging P2X7 purinoceptor activity in dystrophic muscles and also triggering chronic 
inflammation and immune responses that exacerbate the dystrophic pathology. Studies in 
mouse models of MD demonstrated that P2X7 antagonists are good candidates for rapid re-
purposing for the treatment of these highly debilitating diseases. P2X7 therapy is not 
constrained by causative mutations in both DMD and LGMDs. It could therefore be used in 
all patients irrespective of their genetic defect and may be effective in alleviating both muscle 
and non-muscle abnormalities of DMD. Finally, specific targeting of inflammatory/immune 
functions via P2X7 inhibition could not only reduce the dystrophic muscle damage but also 
prevent immunization by dystrophin re-expression through molecular therapies.
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Figure Legend
 Fig 1. The involvement of P2X7 purinoceptors in the dystrophic pathology. Loss of 
dystrophin and/or sarcoglycans affects myofibers (1). Dying muscle release large quantities 
of DAMPs, including eATP (2) whereas deficiency of α-sarcoglycan (3) leads to reduced 
eATP hydrolysis. Resulting greatly elevated levels of eATP and DAMPs trigger chronic 
inflammation (4). Infiltrating cells including T-lymphocytes, granulocytes (GrC), dendritic 
cells and macrophages (M) cause further damage to myofibers (5), while chronically 
elevated levels of inflammatory mediators affect brain and bone functions (not shown). The 
intracellular Ca2+ build-up via permeable sarcolemma and abnormalities of Ca2+ signalling 
pathways exacerbate myofibre injury (6). Inflammation induces muscle regeneration by 
activating satellite cells (7), subsequent myoblast proliferation, migration to damaged sites 
and repair (8). However, chronic inflammation and high eATPe levels reduce repair of 
dystrophic muscle by promoting the M1 over the pro-regenerative M2 macrophages (M2M) 
and by affecting myogenic cell functions. Moreover, high eATP levels combined with P2X7 
over-expression contribute to dystrophic myoblast death (9) and thus reduce muscle 
regeneration further still.
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